Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy

Abstract

Abstract Describe a novel use for a kinase inhibitor, imatinib, in young children with a known activated somatic mutation in PDGFR‐beta. Two patients with infantile myofibromatosis treated with imatinib. Case description of evaluation, diagnosis and treatment decisions for infantile myfibromatosis of the head and neck. Description of medical therapy for infantile myofibromatosis in these patients. For function threatening myofibromas of a known genotype, in infants, targeted medical therapy is a treatment option.

Keywords

• imatinib
• Infantile myofibromatosis
• PDGFRB
• precision medicine